Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06842433

The NUTRIOME Study - a Data-driven Precision Nutrition Intervention

The overall objective of this multi-center study is to use metabolic response data from different dietary challenges to develop personalized dietary advice. Effectiveness of this personalized dietary advice compared to a general healthy diet based on national dietary guidelines on markers of cardio-metabolic health will be tested.

A total of 120 men and women who meet all inclusion criteria and none of the exclusion criteria will be invited to participate. The study will be conducted at three sites: Chalmers University of Technology (Sweden), University of Wageningen (Netherlands), and University of Oslo (Norway), with 40 participants per site.The study is conducted in two parts. The first part, the characterization phase, is a three-way randomized, controlled cross-over design, featuring one-day meal tests with isocaloric meals containing different carbohydrate, fat and protein quantity as well as quality. Based on the metabolic response to the meal tests a personalized diet will be constructed. In the second part, the main intervention, effectiveness of this personalized dietary advice compared to a general healthy diet will be tested in a six week parallel group intervention study.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Metabolic Control

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wageningen University and Research, Human research unit, Wageningen, Netherlands

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women
  • Age 40 to 70 years
  • Body mass index (BMI) 27-35 kg/m2
  • Signed informed consent

Exclusion criteria

  • History of diagnosed cardiovascular disease (e.g. stroke, heart disease)
  • Diagnosed type 1 or type 2 diabetes
  • Finger prick glucose test at screening indicating diabetes (fasting >6.9 mmol/L; non-fasting >11.0 mmol/L)
  • Antibiotic use in the last 3 months
  • Taking medication that can interfere with the planned outcome measures, as judged by the study physician (e.g. peroxisome proliferator-activated receptor-α [PPAR-α] or PPAR-γ agonists [fibrates], sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, repaglinide, nateglinide and insulin, chronic use of NSAIDs). Statins and hypertension medication are allowed if the medication regimen has been stable for the last three months
  • Stomach and gastrointestinal conditions (e.g. Morbus Chron, Ulcerative colitis, irritable bowel syndrome, malabsorption, colostomy, bowel resection, gastric bypass surgery etc.)
  • History of major gastrointestinal surgery
  • Anaemia: Hb concentrations < 8.5 mmol/L for men and < 7.5 mmol/L for women
  • Recent blood donation (within 2 months prior to the screening)
  • Recent participation in another intervention study (within 2 months prior to the screening)
  • Allergy or intolerance to medical skin adhesives
  • Chronic or acute inflammatory conditions (e.g., rheumatoid arthritis, psoriatic arthritis)
  • Autoimmune disorders
  • Thyroid disorders
  • Significant renal or liver dysfunction or chronic kidney or liver disease
  • Known food allergies/intolerances to intervention foods or food products used in the study
  • Following specific dietary regimen that could impact results or not suitable for the study design (e.g. vegetarian, vegan)
  • Habitual tobacco consumption (e.g. smoking, use of snus, vaping)
  • Alcohol intake ≥ 14 alcoholic beverages/week for women and ≥ 21 alcoholic beverages/week for men
  • Current or planned pregnancy or lactating
  • Other serious medical conditions that could interfere with participation or study outcomes
  • Unable to sufficiently understand written and spoken national language (where the study centre is located) to provide written consent and understand information and instructions from the study personnel.
  • Deemed unsuitable for participation in the trial, for any reason, as judged by the research physician or PI.
  • Working at the division conducting the trial at any of the three study centres.
  • Do not have a mobile phone that is suitable for the use of a research app.

Treatment and study plan

General healthy diet

Other

General healthy diet based on national health dietary guidelines.

Personalized diet

Other

Personalized diet will be based on an algorithm considering the individuals' postprandial glucose, triglycerides and inflammation markers to each of the three study meals in the characterization phase (Phase I) matched with established knowledge about the effects of specific foods on such metabolic parameters.

Primary outcomes

  1. Glucose postprandial

    Time frame: 6 weeks

    Difference between groups in postprandial glucose in response to a mixed meal tolerance test.

  2. Triglycerides postprandial

    Time frame: 6 weeks

    Difference between groups in postprandial triglycerides in response to a mixed meal tolerance test.

  3. Interleukin-6 postprandial

    Time frame: 6 weeks

    Difference between groups in postprandial interleukin-6 in response to a mixed meal tolerance test.

Secondary outcomes

  1. Inflammatory markers in blood

    Time frame: 6-hour meal test

    Differences in immunological responses (such as cytokines, lipopolysaccharides, GlycA) between test meals in the characterization phase of the study.

  2. Appetite

    Time frame: 6-hour meal test

    Differences in self-reported appetite measured using a visual analogue scale between test meals in the characterization phase of the study.

  3. Gut microbiome

    Time frame: 6-hour meal test

    Differences in fecal microbiome between test meals in the characterization phase of the study.

  4. Metabolome

    Time frame: 6-hour meal test

    Differences in metabolome (plasma, urine and feces) between test meals in the characterization phase of the study.

  5. Lipid metabolism

    Time frame: 6-hour meal test

    Differences in lipid metabolism between test meals in the characterization phase of the study.

  6. Glycemic variability

    Time frame: 4 weeks

    Differences in glycemic variability across the different meals and the OGTT throughout the characterization phase of the study.

  7. Gastrointestinal hormones

    Time frame: 6-hour meal test

    Release of gastrointestinal hormones (such as GLP-1, CCK) in response to the test meals in the characterization phase of the study.

  8. Fecal proteome

    Time frame: 6-hour meal test

    Differences in fecal proteome between test meals in the characterization phase of the study.

  9. PBMC Transcriptome

    Time frame: 6-hour meal test

    Differences in peripheral blood mononuclear cell gene expression between test meals in the characterization phase of the study.

  10. PBMC Epigenome

    Time frame: 6-hour meal test

    Differences in peripheral blood mononuclear cell epigenome between test meals in the characterization phase of the study.

  11. PBMC Immunometabolism

    Time frame: 6-hour meal test

    Differences in peripheral blood mononuclear cell immunometabolism between test meals in the characterization phase of the study.

  12. Metabolome

    Time frame: 6 weeks

    Difference in metabolome (plasma, urine and feces) between personalized diet and general healthy diet in the intervention phase of the study.

  13. PBMC Epigenome

    Time frame: 6 weeks

    Difference in peripheral blood mononuclear cell epigenome between personalized diet and general healthy diet in the intervention phase of the study.

  14. PBMC Transcriptome

    Time frame: 6 weeks

    Difference in peripheral blood mononuclear cell transcriptome between personalized diet and general healthy diet in the intervention phase of the study.

  15. PBMC Immunometabolism

    Time frame: 6 weeks

    Difference in peripheral blood mononuclear cell immunometabolism between personalized diet and general healthy diet in the intervention phase of the study.

  16. Fecal proteome

    Time frame: 6 weeks

    Difference in fecal proteome between personalized diet and general healthy diet in the intervention phase of the study.

  17. Gut microbiome

    Time frame: 6 weeks

    Difference in fecal microbiome between personalized diet and general healthy diet in the intervention phase of the study.

  18. Inflammatory markers in blood

    Time frame: 6 weeks

    Differences in immunological responses (such as cytokines, lipopolysaccharides, GlycA) to mixed meal tolerance tests between personalized diet and general healthy diet in the intervention phase of the study.

  19. Glycemic variability

    Time frame: 6 weeks

    Differences in glycemic variability between personalized diet and general healthy diet in the intervention phase of the study.

  20. Data-driven prediction of response to intervention

    Time frame: 6 weeks

    Data-driven prediction of primary and other outcomes to personalized diet vs. general healthy diet using metabolome, gut microbiome, epigenome, transcriptome, proteome, immunometabolism, health measures, lifestyle and metabolic markers as determinants.

Other outcomes

  1. Dietary biomarkers

    Time frame: 6-hour meal test and 6 week intervention

    Exploratory analysis of blood, urine and feces to find potential biomarkers reflecting dietary intake in the characterization and intervention phase of the study.

  2. Responsivness to diet

    Time frame: 6-hour test meal and 6 week intervention

    Exploration of underlying mechanisms behind response/non-response to personalized and general healthy diet using data from both the characterization phase (meal test) and the primary 6-week intervention.

  3. Gastric emptying

    Time frame: 6-hour test meal

    Gastric emptying will be assessed by breath test at one of the test meals in a sub-group of participants (Swedish and Norwegian site).

  4. Gastric passage time

    Time frame: 6-hour meal test and 6 week intervention

    Gastric passage time will be assessed using the blue dye method.

Study contacts

Contact information is provided by the study sponsor or research team.

Rikard Landberg, PhD

CONTACT

[email protected]

+46723509386

Sponsors and collaborators

Lead sponsor

Chalmers University of Technology

Other

Collaborators

  • German Cancer Research Center
  • Maastricht University
  • Polish Academy of Sciences
  • University College Dublin
  • University of Copenhagen
  • University of Oslo
  • University of Oulu
  • Wageningen University

Registry information

Official study title

The NUTRIOME Meal Study - a Data-driven Precision Nutrition Intervention Study Using Meal Responses

Acronym: NUTRIOME

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 24, 2025
Registry last updated
Mar 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.